All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Development of Zandelisib for B-cell Malignancies Discontinued Outside of Japan

December 6th 2022

The development of zandelisib for the treatment of B-cell malignancies has been discontinued outside of Japan.

Sylvester Celebrates Inaugural Cancer Survivorship Symposium

December 6th 2022

More than 160 attendees took part in a day of learning and collaboration as Sylvester Comprehensive Cancer Center hosted the inaugural Cancer Survivorship Symposium.

Dana-Farber Researchers to Present Findings at San Antonio Breast Cancer Symposium

December 6th 2022

Researchers from Dana-Farber Cancer Institute will present more than 30 research studies at the 44th annual San Antonio Breast Cancer Symposium on December 7-10th.

FDA Grants Breakthrough Therapy Designation to Revumenib in Relapsed/Refractory KMT2A-rearranged Acute Leukemia

December 6th 2022

The FDA has granted a breakthrough therapy designation to revumenib for the treatment of adult and pediatric patients with relapsed/refractory acute leukemia harboring a KMT2A rearrangement.

Prominence of HER2 Alterations in NSCLC Trigger Questions About Best Practices

December 6th 2022

As new classes of agents deliver promising results for patients with HER2-mutant non–small cell lung cancer, new questions surrounding optimal identification tactics, sequencing, and treatment of patients arise.

Budigalimab Plus ABBV-151 Demonstrates Variable Activity Across Locally Advanced or Metastatic Solid Tumors

December 6th 2022

The addition of budigalimab to ABBV-151 was well tolerated and significantly enhanced responses in patients with locally advanced or metastatic solid tumors.

Antibody-Drug Conjugates Expand HER2+ Breast Cancer Treatment Options

December 5th 2022

Erika P. Hamilton, MD, discusses anticipated updates from DESTINY-Breast02 and DESTINY-Breast03 that will be presented at the 2022 San Antonio Breast Cancer Symposium, how trastuzumab emtansine will fit into the armamentarium in light of the efficacy of trastuzumab deruxtecan, and additional data to expect from SABCS regarding ADCs and beyond.

A Breakthrough for the “Lab Brat”

December 5th 2022

Building on research his father conducted decades earlier, Robert Orlowski, MD, PhD, redefined myeloma treatment.

Neoadjuvant Vidutolimod Plus Nivolumab Demonstrates Favorable Efficacy, Tolerability in Resectable Melanoma

December 5th 2022

The combination of neoadjuvant vidutolimod and nivolumab elicited high response rates and was well tolerated in patients with high-risk, resectable melanoma, according to final results from a phase 2 trial.

Phase 1 Trial Pauses Enrollment for Evaluation of TH1902 in Sortilin-Expressing Cancers

December 5th 2022

Enrollment has been paused for a phase 1 trial investigating the peptide-drug conjugate TH1902 for the treatment of patients with sortilin-expressing cancers.

Pluvicto Improves rPFS in PSMA-Positive mCRPC

December 5th 2022

Treatment with lutetium Lu 177 vipivotide tetraxetan led to a statistically significant and clinically meaningful improvement in radiographic progression-free survival following treatment with an androgen receptor pathway inhibitor in patients with prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer.

Medical Oncologist Ke Ning, MD Joins Florida Cancer Specialists & Research Institute Sarasota Downtown Clinic

December 5th 2022

Florida Cancer Specialists & Research Institute welcomes Board-certified medical oncologist Ke Ning, MD to the Sarasota Downtown clinic team.

MRD Detection Emerges as a Catalyst for Advances in Colon Cancer

December 5th 2022

For patients with colon cancer, traditional clinical and pathologic risk factors may soon take a backseat as stratification tactics for determining optimal candidates for adjuvant chemotherapy.

Sintilimab Plus Anlotinib Improves Responses, PFS Vs Chemotherapy in Untreated NSCLC

December 5th 2022

The combination of sintilimab and anlotinib elicited improved responses and progression-free survival compared with chemotherapy in previously untreated patients with metastatic non–small cell lung cancer.

Olaparib Plus Durvalumab and Bevacizumab Provides Durable Survival in Non-Germline, BRCA+ Relapsed Ovarian Cancer

December 4th 2022

Olaparib plus durvalumab and bevacizumab led to prolonged survival and disease control without causing additive toxicity in patients with non-germline BRCA-mutated, platinum-sensitive, relapsed ovarian cancer.

Leading by Example

December 3rd 2022

A girl who grew up in a small South Dakota town, Julie M. Vose, MD, MBA, grew into a dynamo who revolutionized lymphoma treatment and led the most prominent oncology organization in the world.

EMA Accepts Marketing Authorization Application for Momelotinib in Myelofibrosis

December 2nd 2022

The European Medicines Agency has accepted a marketing authorization application for momelotinib as a treatment for patients with myelofibrosis.

FDA Issues Complete Response Letter for Omburtamab BLA for Pediatric Metastatic Neuroblastoma

December 2nd 2022

The FDA has issued a complete response letter to the biologics license application seeking the approval of 131I-omburtamab for the treatment of pediatric patients with central nervous system/leptomeningeal metastases from neuroblastoma.

Fox Chase Study Reveals Mechanism for Repairing DNA Damage Caused by Environmental Triggers

December 2nd 2022

It’s long been known that DNA damage caused by environmental triggers, as well as other sources of oxidative stress, contribute to the development and progression of a wide variety of cancers.

Dostarlimab Plus Chemotherapy Combo Meets PFS End Point in Advanced or Recurrent Endometrial Cancer

December 2nd 2022

Dostarlimab plus standard-of-care chemotherapy, followed by dostarlimab alone, produced a statistically significant and clinically meaningful improvement in progression-free survival vs chemotherapy alone in patients with primary advanced or recurrent endometrial cancer.